Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

NCT07169279 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT07169279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Phase 2
Overall status
Recruiting
Start date
November 19, 2025
Completion date
March 31, 2032
Enrollment
77 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia